Hemogenyx Pharmaceuticals PLC Announces Half-year Financial Report

Hemogenyx Pharmaceuticals plc (LSE: HEMO) has released its unaudited half-year financial report for the six months ended 30 June 2026, describing progress toward dose escalation for its HG-CT-1 FLT3-targeted, autologous CAR-T therapy for relapsed/refractory AML. The company says it submitted a second Annual IND report to the FDA in April 2026, summarizing one year of trial activity and results from three adult patients treated at the first, lowest dose level. It reports that manufacturing for HG-CT-1 has been established in Estonia in preparation for technology transfer, with Cellin Technologies OÜ named for early commercialization. Operating costs were reduced after outsourcing HG-CT-1 manufacture to Made Scientific. Hemogenyx raised £5.6 million in H1 2026, including £3.0 million from a small group of institutional investors.